EXAI vs. CABA, KYTX, NVAX, HUMA, PRME, VALN, PROK, HLVX, ALEC, and ALLO
Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX), Novavax (NVAX), Humacyte (HUMA), Prime Medicine (PRME), Valneva (VALN), ProKidney (PROK), HilleVax (HLVX), Alector (ALEC), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
Exscientia (NASDAQ:EXAI) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.
Cabaletta Bio received 66 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 69.44% of users gave Cabaletta Bio an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
In the previous week, Exscientia had 20 more articles in the media than Cabaletta Bio. MarketBeat recorded 22 mentions for Exscientia and 2 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.80 beat Exscientia's score of 0.08 indicating that Cabaletta Bio is being referred to more favorably in the news media.
Exscientia currently has a consensus price target of $9.75, indicating a potential upside of 96.97%. Cabaletta Bio has a consensus price target of $34.33, indicating a potential upside of 180.96%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Exscientia.
Exscientia has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.
41.6% of Exscientia shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cabaletta Bio has a net margin of 0.00% compared to Exscientia's net margin of -737.10%. Exscientia's return on equity of -36.44% beat Cabaletta Bio's return on equity.
Cabaletta Bio has lower revenue, but higher earnings than Exscientia. Cabaletta Bio is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
Summary
Cabaletta Bio beats Exscientia on 10 of the 17 factors compared between the two stocks.
Get Exscientia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exscientia Competitors List
Related Companies and Tools
